Five firms to license MPP’s dolutegravir
Executive Summary
Five generics manufacturers have signed sublicensing agreements with the Medicines Patent Pool (MPP) enabling the firms to develop and sell dolutegravir in “more than 100 developing countries”. Among the companies are South Africa’s Adcock Ingram and South Korea’s Celltrion, the first firms from these regions to enter sub-licensing deals with the Pool. The others are China’s Langhua Pharma, plus Arene Lifesciences and Mangalam Drugs & Organics in India.